Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
收藏NBER2011-06-01 更新2025-01-04 收录
下载链接：
https://www.nber.org/papers/w17188
下载链接
链接失效反馈官方服务：
资源简介：
With increasing frequency, generic drug manufacturers in the United States are able to challenge the monopoly status of patent-protected drugs even before their patents expire. The legal foundation for these challenges is found in Paragraph IV of the Hatch-Waxman Act. If successful, these Paragraph
提供机构：
美国国家经济研究局
创建时间：
2011-06-01
